We have previously reported that noncompetitive inhibitors of ribonucleotide reductase including hydroxyurea (HU) inhibit SAMHD1 ara-CTPase activity, thereby potentiating sensitivity to ara-C in AML.36 This evidence concerns the gene SAMHD1 and acute myeloid leukemia.